News

Dishman Celebrates a Decade of Success Since Acquisition of CARBOGEN AMCIS


11 August 2016

AHMEDABAD, INDIA, August 11, 2016 – Dishman Pharmaceuticals and Chemicals Ltd (DPCL), leading outsourcing partner for the global pharmaceutical industry, today marked the 10-year anniversary of its acquisition of CARBOGEN AMCIS. A significant milestone of growth and development of Indian-Swiss business relations.
 
CARBOGEN AMCIS (headquarters in Bubendorf, Switzerland) and Dishman Pharmaceuticals and Chemicals Ltd (headquarters in Ahmedabad, India) are both suppliers of complex services and products for the global pharmaceutical industry. In addition, each company belongs to the high-tech end of their country’s respective field.

“The acquisition by the Dishman Group of two pharmaceutical businesses from the company formerly known as Solutia Europe, which together formed CARBOGEN AMCIS, is a brilliant example of the impressive achievements companies can make through collaboration,” said Mark Griffiths, CEO, Dishman Group. “I am very proud of all our employees’ contributions to a decade of not only team work and business relationships, but also the sharing of cultures between India and Switzerland.”

More than 380 official representatives, customers, business partners, investors and employees will gather to celebrate this success during a Fusion event in Bubendorf on August 11, 2016.
 
A portion of the ceremony will pay tribute to Mr. J.R. Vyas, Chairman, Owner of the Dishman Group and Founder of Dishman Pharmaceuticals and Chemicals Ltd.

“The ceremony gives us an opportunity to thank Mr. Vyas for his 10-year contribution to the success of this collaboration,” said Griffiths. “His achievement in seamlessly bringing two cultures together is remarkable, and I look forward to watching him lead Dishman Group into further growth and expansion for years to come.”

“Loyal clients, consistent quality confirmed through numerous successful audits by international regulators, as well as further planned expansions make a bright future for Dishman Group,” commented Mr. Vyas. “I am honoured to play a role in continuing to build a positive outlook for Indian-Swiss collaborative business ventures.”

Since 2006, both companies have played crucial roles for the group’s growth. The Dishman Manchester site was successfully integrated into CARBOGEN AMCIS in 2007, followed by the integration of the Shanghai site in 2015. CARBOGEN AMCIS’ footprint and capacity expanded through additional site acquisitions (Riom, France in 2012; Vionnaz, Switzerland in 2014) and the recently announced facility expansion in Bubendorf through the acquisition of land and buildings of GEA Pharma Systems AG.

Today, the multi-million dollars service provider operates ten sites (two in India, one in Netherlands, four in Switzerland, one in the United Kingdom, one in France, and one in China), employing more than two thousand employees, and records a highly successful audit history.

###

CARBOGEN AMCIS AG (www.carbogen-amcis.com) is a leading service provider, offering a portfolio of drug-development and commercialization services to the pharmaceutical and biopharmaceutical industry at all stages of drug development. The integrated services provide innovative chemistry solutions to support timely and safe drug development allowing customers to make the best use of available resources. CARBOGEN AMCIS AG is owned by Dishman Pharmaceuticals and Chemicals Ltd, Ahmedabad, India.
 
Dishman Pharmaceuticals and Chemicals Ltd (www.dishmangroup.com) is a global outsourcing partner for the pharmaceutical industry, offering a portfolio of development, scale-up and manufacturing services. The Dishman Group improves its customers’ businesses by providing a range of development and manufacturing solutions at locations in Europe and in India.

Dishman Netherlands awarded for its Corporate Social Responsibility.


2 February 2016

AHMEDABAD, INDIA, February 1, 2016 – Dishman Pharmaceuticals and Chemical Ltd (DPCL), leading outsourcing partner for the global pharmaceutical industry, has announced that its facility located in Netherlands has been awarded by the Business Association in Veenendaal with the Corporate Social Responsibility Prize.

Dishman Netherlands, located in Veenendaal and part of  DPCL is active in the marketing/sales and manufacture of Vitamin D analogues, Vitamin D, Cholesterol and lanolin related products for key markets as pharmaceutical, cosmetic, feed, food, shrimp farming and industrial applications.

On January 4 2016, the Corporate Social Responsibility systems of Dishman Netherlands were awarded the Business Association of the City of Veenendaal CSR prize. Over the last 3 years, this prize has been awarded to companies that have demonstrated their outstanding performance in Corporate Social Responsibility with a clear and positive contribution to life in the City of Veenendaal. Nominated companies have been recognised for their capacity to combine economic development with environmental and social criteria. Also called Triple P (People, Planet and Profit), the Corporate Social Responsibility is a  vision that companies have embedded into their business focussing on  future generations and to minimize their impact on their local environment and elsewhere in the world.

After deliberation the jury, composed by Town Council representatives and members of the Business Association in Veenendaal, announced their selected winner from several nominated companies.

During the annual New Year's reception of the Business Association in Veenendaal, Dishman Netherlands was presented the award by Mr Wouter Kolff, Mayor of Veenendaal, who has expressed his acknowledgement to Dishman Netherlands’ commitment in terms of Corporate Social Responsibility. “Dishman has a clear comprehensive vision on CSR and plays an important leadership role. The Management team and the staff have worked on an intensive process that is certainly still on-going. The ambition is to keep this leader position and to continue to expand efforts on CSR. It is hard work towards an energy-neutral production using 'green technology'.” commented Wouter Kolff. 

By rewarding Dishman Netherlands the Jury wanted to emphasise its positive energy and its enthusiasm. “Furthermore Dishman is very active in in the field of social action and involved in the Veenendaal corporate community” concluded Kolff.

“We are delighted and very proud” commented Jeroen de Jong, Manager QHSE (Quality Health Safety and Environment), who received the prize on the behalf of Dishman Management team at the ceremony. “In the past years, we brought important efforts to improve our Corporate Social Responsibility and share our action with interested parties. For example we organised an “open doors day”, which has drew in 1200 visitors this year.
We also invested research into sustainable products”

“Dishman Netherlands is fully aware of the impact that its activities might have on people and environment. We have and take the responsibility for the reduction and prevention of these impacts. Dishman Netherlands has formulated a clear and transparent policy towards all health, safety and environmental aspects. This is also on line with our customers’ needs. We know they need to have a total confidence in our Quality Management policy.” said Mark Ipema VP Operations, Dishman Netherlands.

###

Dishman Pharmaceuticals and Chemicals Ltd (www.dishmangroup.com) is a global outsourcing partner for the pharmaceutical industry, offering a portfolio of development, scale-up and manufacturing services. Dishman Group improves its customers’ businesses by providing a range of development and manufacturing solutions at locations in Europe and in India.

Dishman has been awarded manufacture of SIRTURO® (bedaquiline) API


24 September 2015

 Dishman Pharmaceuticals and Chemicals Limited (Dishman), a leading global manufacturer of pharmaceutical active ingredients, announced today that it holds a license agreement from Janssen Pharmaceutica NV, one of the Janssen Pharmaceutical Companies of Johnson & Johnson (Janssen) to produce the Active Pharmaceutical Ingredient (API) of SIRTURO® (bedaquiline), a medicine used in the treatment of Multi-Drug Resistant Tuberculosis (MDR-TB).

In 2008 Janssen had contracted Dishman to conduct full chemical synthesis of this API at their manufacturing facility in Bavla, India. Janssen subsequently registered Dishman as a manufacturer of API with the USFDA, European Medicines Agency and several other Asian regulatory authorities. Recently, Dishman has started supplying Janssen with the global demand of this API.

Speaking on behalf of the company Dishman Chairman, Mr. J R Vyas, said:  “We are extremely proud of the responsibility entrusted to our team and the important role we are able to play in combatting MDR-TB.  India is a country significantly burdened by this disease and we fully understand its devastating impact on people’s lives.  Our team are working diligently to ensure we are well placed to support Janssen in addressing the demand for bedaquiline in high-burden TB areas.”

Tuberculosis (TB) is a major public health concern in India with the World Health Organization estimating there are more than 2.8 million cases of TB1.  In particular, the burden of MDR-TB in India, is among the most significant in the world with an estimated 64,000 cases2 , and for those diagnosed with this deadly disease, fewer than half are treated successfully3 .

In January 2015, SIRTURO® (bedaquiline) received approval from the Drugs Controller General of India for use in adults (>18 years) as part of combination therapy of pulmonary tuberculosis due to multidrug-resistant Mycobacterium tuberculosis when an effective treatment regimen cannot otherwise be provided.  This approval provides for access to bedaquiline under the Revised National TB Control Program through its Programmatic Management of Drug Resistant TB framework in order to ensure appropriate use.

About Multidrug-Resistant Tuberculosis (MDR-TB)
MDR-TB is a particularly complicated form of TB characterised by resistance to at least two of the standard four-drug, anti-TB drugs4.  Inadequately treated patients are likely to increase selective pressure, allowing resistant bacteria to thrive and pose a significant transmission risk to the general population. Without significant public health intervention, MDR-TB is projected to infect more than two million people between 2011 and 20155.

1 Ministry of Health and Family Welfare. TB India 2014 – Annual Status Report. Available at: http://www.tbcindia.nic.in/pdfs/TB%20INDIA%202014.pdf   Accessed January 2015.
2 Ministry of Health and Family Welfare. TB India 2014 – Annual Status Report. Available at: http://www.tbcindia.nic.in/pdfs/TB%20INDIA%202014.pdf Accessed January 2015.
3 WHO. Global Tuberculosis Report 2014. Available at http://apps.who.int/iris/bitstream/10665/137094/1/9789241564809_eng.pdf?ua=1 Accessed January 2015
4 WHO. Multidrug-Resistant Tuberculosis, Online Q&A. February 2012. Available at http://www.who.int/features/qa/79/en/index.html Accessed October 2014.
5 WHO. Partners call for increased commitment to tackle MDR-TB. 23 March 2011. Available at http://www.who.int/mediacentre/news/releases/2011/TBday_20110322/en/index.html

###

Dishman Group (www.dishmangroup.com) is a global outsourcing partner for the pharmaceutical industry, offering a portfolio of development, scale-up and manufacturing services. Dishman Group improves its customers’ businesses by providing a range of development and manufacturing solutions at locations in Europe, China and India.

Successful FDA inspection at the Netherlands Dishman site


9 February 2015

AHMEDABAD, INDIA, February 9, 2015 – Dishman Group, leading outsourcing partner for the global pharmaceutical industry, has announced the successful completion of an inspection by the U.S. Food and Drug Administration (FDA) for its Netherlands site.

The inspection, carried out by an USFDA investigator, was planned for 5 days but lasted 3 days, starting on January 24, 2015 and concluding on  January 26, 2015. The inspection confirmed the site is compliant with the principles and guidelines of current Good Manufacturing Practices (cGMP).

“This success is the result of great team work. I would like to express my thanks to my staff. The entire team contributed to this successful inspection and I’m very proud of them,” commented Mark Ipema, VP Operations, Dishman Netherlands. “The result we have achieved is of great importance not only to Dishman Netherlands, but also to the entire Dishman Group, demonstrating our commitment to meeting and exceeding customer requirements.”

Dishman Netherlands, located in Veenendaal, is active in the marketing, sales and manufacture of Vitamin D analogues, Vitamin D, Cholesterol and lanolin related products for key markets as pharmaceutical, cosmetic, food, feed and industry applications. ISO 9001 and 14001 certified, the site is equipped of a full cGMP production laboratory.

“I’m very satisfied that our team at Dishman Netherlands have been able to demonstrate their compliance to the GMP’s” said Mark Griffiths, Dishman CEO. “Quality is central to the Dishman business and we constantly strive to ensure that worker safety and product quality are never compromised. This is a great result, rewarding all efforts of Dishman Netherlands, but also other Dishman sites, to make sure quality and efficiently are our priority.”

"We are delighted to have received a positive audit outcome and are proud of our team at Dishman Netherlands," commented Janmejay Vyas, Chairman of Dishman.

###

Dishman Group (www.dishmangroup.com) is a global outsourcing partner for the pharmaceutical industry, offering a portfolio of development, scale-up and manufacturing services. Dishman Group improves its customers’ businesses by providing a range of development and manufacturing solutions at locations in Europe, China and India.

 

 

News

11 August 2016
Dishman Celebrates a Decade of Success Since Acquisition of CARBOGEN AMCIS

2 February 2016
Dishman Netherlands awarded for its Corporate Social Responsibility.

24 September 2015
Dishman has been awarded manufacture of SIRTURO® (bedaquiline) API

9 February 2015
Successful FDA inspection at the Netherlands Dishman site

VIEW NEWS ARCHIVE